XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborations - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 22 Months Ended
Apr. 30, 2016
USD ($)
Unit
Jan. 31, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Difference between cash proceeds received and estimated fair value of preferred units           $ 2,600,000    
Collaboration revenue     $ 4,869,000 $ 1,688,000 $ 10,852,000 4,351,000    
Novartis [Member] | Class A Preferred Units [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Proceeds from issuance of preferred stock   $ 9,000,000            
Estimated fair value of units   11,600,000            
Difference between cash proceeds received and estimated fair value of preferred units   2,600,000            
Novartis [Member] | Maximum [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Development based milestone payments under agreement   30,300,000            
Regulatory based milestone payments for first indication   50,000,000            
Regulatory based milestone payments for second indication   50,000,000            
Sales based milestone payments under agreement   100,000,000            
Novartis [Member] | Collaborative Arrangement [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Collaboration revenue             $ 19,400,000  
Technology access fees   20,000,000            
Quarterly research payments   $ 1,000,000            
Research term   5 years            
Collaboration revenue     2,000,000 $ 1,700,000 5,700,000 $ 4,400,000 11,700,000  
Deferred revenue     7,700,000   7,700,000   7,700,000 $ 10,300,000
Novartis [Member] | Collaborative Arrangement [Member] | Upfront Technology Access Payment [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Collaboration revenue   $ 10,000,000            
Novartis [Member] | Collaborative Arrangement [Member] | Maximum [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total research funding   $ 20,000,000            
Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Collaboration revenue $ 75,000,000              
Collaboration revenue     2,900,000   5,200,000      
Deferred revenue     $ 69,900,000   $ 69,900,000   69,900,000  
Purchase of common stock through private placement $ 50,000,000              
Percentage of obligated fund on research and development costs 50.00%              
Number of accounting based units | Unit 2              
Amount allocated to licenses to targets and associated research activities and evaluation plans $ 63,800,000              
Licenses to targets and associated research activities and evaluation plans performance period 6 years              
Amount allocated to technology collaboration $ 11,200,000              
Revenue Recognition, Multiple-deliverable Arrangements, Allocation to Specific Unit of Accounting         The Company allocated the $75.0 million in fixed consideration to the two units of accounting based on the estimated relative selling price of each deliverable.      
One time collaboration payment $ 25,000,000              
Collaboration term extension period 2 years              
Royalty payment obligation expiration period 12 years              
Termination period of agreement 180 days              
Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member] | Upfront Technology Access Payment [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Collaboration revenue             75,000,000  
Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member] | Research and Development Services [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Collaboration revenue             $ 100,000  
Regeneron Pharmaceuticals Inc. [Member] | Collaborative Arrangement [Member] | Maximum [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Development based milestone payments under agreement $ 25,000,000              
Sales based milestone payments under agreement 185,000,000              
Regulatory based milestone payments under agreement $ 110,000,000